<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The genodermatoses: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The genodermatoses: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The genodermatoses: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teresa S Wright, MD, FAAD, FAAP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The genodermatoses are a large group of inherited disorders with skin manifestations. Many of these disorders are rare. However, the recognition of their skin findings is important not only for the initiation of appropriate therapy but also for the detection of other associated abnormalities, including malignancy, in these frequently multisystem disorders [<a href="#rid1">1-3</a>].</p><p>An overview of the genodermatoses is presented here. Online resources that provide general information about these disorders include <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.orpha.net%2Fconsor%2Fcgi-bin%2Findex.php&amp;token=GFVT0Sy13wt2HNKgDiTNc4%2BP656gH8p%2FKkjdFdeGSWxLAeILwa%2FvJvuKCfQs7QOu1q%2BP%2F0r20e%2Bbz5YQoiKJZg%3D%3D&amp;TOPIC_ID=3004" target="_blank">Orphanet</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2F&amp;token=87jLzclRwWxNoI%2BQq5Gg719fkmhU1%2BHL5BgfqtERBlQ%3D&amp;TOPIC_ID=3004" target="_blank">Online Mendelian Inheritance in Man (OMIM)</a>.</p><p class="headingAnchor" id="H523750890"><span class="h1">DISORDERS WITH MALIGNANT POTENTIAL</span><span class="headingEndMark"> — </span>This group of genodermatoses is of particular importance because of the association of skin findings with the development of malignancies, both cutaneous and noncutaneous  (<a class="graphic graphic_table graphicRef72060" href="/z/d/graphic/72060.html" rel="external">table 1</a>). Examples include basal cell nevus syndrome, Gardner syndrome, Peutz-Jeghers syndrome (PJS), and xeroderma pigmentosum (XP).</p><p class="headingAnchor" id="H523750943"><span class="h2">Basal cell nevus syndrome</span><span class="headingEndMark"> — </span>The basal cell nevus syndrome (nevoid basal cell carcinoma syndrome, Gorlin syndrome, MIM #109400) is a rare disorder of autosomal dominant inheritance that results from germline mutations of the human patched gene (<em>PTCH</em>). (See  <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"</a>.)</p><p>Affected patients have both developmental anomalies and postnatal tumors, especially multiple basal cell carcinomas (BCCs), usually by age 35 years. Most have the following clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>Macrocephaly, frontal bossing, and hypertelorism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bifid ribs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palmar and plantar pitting  (<a class="graphic graphic_picture graphicRef72687" href="/z/d/graphic/72687.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Odontogenic keratocysts, especially in the mandible, which usually develop in adolescence and typically are the presenting sign of the disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medulloblastoma in 3 to 5 percent; meningioma occurs infrequently. (See  <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p>The histologic appearance of the BCCs in basal cell nevus syndrome does not differ from those seen in sporadic cases. The diagnosis should be suspected in patients who present with multiple BCCs, especially at an early age.</p><p>These patients require careful sun protection from infancy and regular skin surveillance by a dermatologist. Radiotherapy should be avoided due to the risk of inducing BCCs in the treatment fields. </p><p class="headingAnchor" id="H523750950"><span class="h2">Gardner syndrome</span><span class="headingEndMark"> — </span>Gardner syndrome consists of familial adenomatous polyposis (FAP, MIM #175100) with associated extraintestinal manifestations [<a href="#rid4">4</a>]. It is inherited as an autosomal dominant disorder caused by mutations in the tumor suppressor gene, adenomatous polyposis coli (<em>APC</em>). (See  <a class="medical medical_review" href="/z/d/html/2598.html" rel="external">"Gardner syndrome"</a>.)</p><p>The most characteristic skin feature is multiple epidermoid cysts. Other findings include desmoid tumors, lipomas, osteomas (especially of the mandible), supernumerary teeth, gastric polyps, and juvenile nasopharyngeal angiofibromas. Congenital hypertrophy of the retinal pigmented epithelium is a reliable and early marker of the disease when it is present. Prophylactic colectomy is recommended because of the nearly universal development of colorectal cancer in affected patients.</p><p>In addition to colorectal adenocarcinoma, patients with FAP are at risk for several extracolonic malignancies, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Duodenal ampullary carcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>Follicular or papillary thyroid cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Childhood hepatoblastoma</p><p class="bulletIndent1"><span class="glyph">●</span>Gastric carcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) tumors (mostly medulloblastomas)</p><p></p><p class="headingAnchor" id="H523750957"><span class="h2">Peutz-Jeghers syndrome</span><span class="headingEndMark"> — </span>Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant condition characterized by distinctive mucocutaneous pigmentations and multiple hamartomatous polyps in the gastrointestinal tract [<a href="#rid5">5</a>]. Most cases are associated with mutations in the tumor suppressor gene <em>STK11</em> (serine/threonine kinase 11)/<em>LKB1</em> [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p>The characteristic mucocutaneous pigmentations (lentigines) of PJS are present in more than 95 percent of patients and are caused by pigment-laden macrophages in the dermis. They are typically flat, blue-gray to brown spots 1 to 5 mm in size that look like freckles. However, the onset and location of PJS spots are different from those of freckles.</p><p>Lentigines occur most commonly on the lips and perioral region (94 percent), hands (74 percent), buccal mucosa (66 percent), and feet (62 percent)  (<a class="graphic graphic_picture graphicRef80815" href="/z/d/graphic/80815.html" rel="external">picture 2</a>) [<a href="#rid7">7</a>]. They also occur on the nose, perianal area, and genitals and are rarely found in the intestines. They usually occur during the first one to two years of life, increase in size and number over the ensuing years, and finally fade after puberty, with the exception of those on the buccal mucosa.</p><p>Gastrointestinal hamartomatous polyps are present in most patients with PJS, and patients may develop gastrointestinal malignancy. The risk of nongastrointestinal cancers, including adenocarcinomas of the breast, cervix, pancreas, uterus, and ovaries, is also increased.</p><p class="headingAnchor" id="H1252940545"><span class="h2">Hereditary leiomyomatosis and renal cell cancer</span><span class="headingEndMark"> — </span>Hereditary leiomyomatosis and renal cell cancer (HLRCC; MIM #150800) is caused by autosomal dominant, heterozygous mutations in the fumarate hydratase gene (<em>FH</em>) [<a href="#rid8">8</a>]. HLRCC presents in early adulthood with multiple cutaneous leiomyomas, most frequently on the trunk and extremities  (<a class="graphic graphic_picture graphicRef100293 graphicRef100296 graphicRef100292 graphicRef100291" href="/z/d/graphic/100293.html" rel="external">picture 3A-D</a>). Affected women frequently develop uterine leiomyomas at an early age. HLRCC is associated with an increased risk of early-onset, aggressive renal cancer [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">"Hereditary leiomyomatosis and renal cell cancer (HLRCC)"</a>.)</p><p class="headingAnchor" id="H523750964"><span class="h2">Xeroderma pigmentosum</span><span class="headingEndMark"> — </span>Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder caused by mutations in any of eight genes involved in the recognition and repair of ultraviolet radiation (UVR)-induced DNA damage [<a href="#rid10">10</a>]. XP is characterized by increased sensitivity to UVR, early development of pigmentary changes and UVR-induced skin and mucous membrane cancers (beginning in early childhood), and, in some patients, progressive neurodegeneration.</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of XP are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15466.html" rel="external">"Xeroderma pigmentosum"</a>.)</p><p class="headingAnchor" id="H523750971"><span class="h2">Epidermolysis bullosa</span><span class="headingEndMark"> — </span>Patients with particular subtypes of epidermolysis bullosa are at increased risk for cutaneous malignancy. (See  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Skin cancer'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DISORDERS OF KERATINIZATION</span><span class="headingEndMark"> — </span>Keratins are intermediate filament proteins that form the cytoskeleton in all epithelial cells, including the stratified epithelium of the epidermis [<a href="#rid11">11</a>]. Keratins represent the major proteins produced by the keratinocyte, which is the primary cell type of the epidermis. The maturation of basal epidermal cells to the flattened cells that constitute the superficial stratum corneum is known as keratinization [<a href="#rid12">12</a>].</p><p>Over 50 genes that encode keratins have been identified in humans [<a href="#rid13">13</a>]. The phenotype resulting from a particular mutation depends upon the tissue-specific expression pattern of that keratin.</p><p class="headingAnchor" id="H3"><span class="h2">Ichthyoses</span><span class="headingEndMark"> — </span>The ichthyoses are a diverse group of hereditary skin disorders characterized by the accumulation of "fish-like" scales resulting from abnormal epidermal cell kinetics or differentiation  (<a class="graphic graphic_table graphicRef71157" href="/z/d/graphic/71157.html" rel="external">table 2</a>) [<a href="#rid14">14</a>]. The severity of the individual disorders ranges from asymptomatic to life threatening.</p><p>The cornerstone of therapy for all types is aggressive hydration of the skin with emollients. When tolerated, keratolytics also may be used. Severe or extensive involvement may require systemic retinoids.</p><p>Referral to a dermatologist is indicated when basic treatment measures, such as emollients, are not working, when there are complications related to the skin condition, or if the diagnosis is not clear. Biopsy is useful for certain types of ichthyoses or disorders of cornification.</p><p>The major types of inherited ichthyoses are reviewed separately. Information for patients and families/caregivers is available on the website of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=3004" target="_blank">Foundation for Ichthyosis and Related Skin Types</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15474.html" rel="external">"Netherton syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1699.html" rel="external">"Sjögren-Larsson syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Palmoplantar keratodermas</span><span class="headingEndMark"> — </span>These disorders share the common feature of palmar and plantar hyperkeratosis that manifests as thickening and scaling of the palms and soles. The general underlying defect in the majority of the palmoplantar keratodermas is overproduction of a normal or an abnormal keratin in the palms and soles. The majority of cases are mild to moderate, without systemic problems and with autosomal dominant inheritance.</p><p>The keratodermas differ in their mode of inheritance, severity, and extent of involvement and associated features [<a href="#rid15">15,16</a>]. This is illustrated by the following examples of these disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Howel-Evans syndrome is a rare, autosomal dominant diffuse form with onset between 5 and 15 years of age [<a href="#rid17">17</a>]. It has been associated with the early development of esophageal cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vohwinkel syndrome is a rare, autosomal dominant disorder in which patients may have autoamputation of the digits (pseudoainhum) and high-frequency hearing loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Papillon-Lefèvre syndrome is an autosomal recessive condition that presents in the first six months of life. Patients often have severe periodontitis, leading to early dental loss.</p><p></p><p>The clinical presentation, diagnosis, and management of palmoplantar keratodermas are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a>.)</p><p class="headingAnchor" id="H3247114"><span class="h2">Pachyonychia congenita</span><span class="headingEndMark"> — </span>Pachyonychia congenita (PC) is an autosomal dominant disorder caused by mutations in the genes that encode keratins (<em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, and <em>KRT17</em>), the type I and II intermediate filament proteins that form a cytoskeletal network in all epithelial cells [<a href="#rid18">18</a>]. Affected patients present with thickened, discolored nails of the fingers and toes  (<a class="graphic graphic_picture graphicRef52261" href="/z/d/graphic/52261.html" rel="external">picture 4</a>). These changes are present at birth in approximately 50 percent of the affected children [<a href="#rid19">19</a>]. Palmar and plantar hyperkeratoses and hyperhidrosis, follicular keratoses of the knees and elbows, and oral leukoplakia may develop within the first decade of life. Thickened nails and plantar hyperkeratoses may be extremely painful [<a href="#rid20">20</a>].</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of PC are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15504.html" rel="external">"Pachyonychia congenita"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Darier disease</span><span class="headingEndMark"> — </span>Darier disease, also known as Darier-White disease or keratosis follicularis (MIM #124200), is an autosomal dominant disorder caused by mutations in the gene encoding the sarco/endoplasmic reticulum Ca(+2)-ATPase [<a href="#rid21">21</a>]. This results in loss of adhesion between epidermal cells and abnormal keratinization. The disorder is a relatively common genodermatosis with a frequency of up to 1 in 36,000 individuals [<a href="#rid22">22</a>].</p><p>The disorder typically presents in the second decade of life with hyperkeratotic, yellow-brown, greasy-appearing papules that coalesce into verrucous-like plaques  (<a class="graphic graphic_picture graphicRef56168 graphicRef70000" href="/z/d/graphic/56168.html" rel="external">picture 5A-B</a>) [<a href="#rid23">23,24</a>]. The lesions are often pruritic and frequently become purulent and malodorous, especially if infected. Typical sites of involvement are in a seborrheic distribution: trunk, face, scalp, and groin. Nails may demonstrate red/white vertical stripes, subungual hyperkeratosis, and notching of the distal nail margins  (<a class="graphic graphic_picture graphicRef81865" href="/z/d/graphic/81865.html" rel="external">picture 6</a>). Palmar keratosis and pits often are present.</p><p>The course of the illness is chronic and persistent, with characteristic worsening in summer months. Darier disease is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">GENETIC BLISTERING DISORDERS</span><span class="headingEndMark"> — </span>These disorders result from abnormalities in the cohesion of the layers of the epidermis. They result in separation of the layers in response to minimal injury.</p><p class="headingAnchor" id="H13"><span class="h2">Epidermolysis bullosa</span><span class="headingEndMark"> — </span>Epidermolysis bullosa (EB) constitutes a clinically and genetically heterogeneous group of rare inherited disorders characterized by marked skin and mucosal fragility caused by mutations in skin structural proteins. There are four major types of EB, based upon the ultrastructural level of tissue cleavage in the skin: EB simplex, junctional EB, dystrophic EB, and Kindler EB  (<a class="graphic graphic_table graphicRef76897" href="/z/d/graphic/76897.html" rel="external">table 3</a>) [<a href="#rid25">25,26</a>]. Many subtypes have been identified based upon clinical, pathophysiologic, and molecular criteria  (<a class="graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262 graphicRef81536" href="/z/d/graphic/77709.html" rel="external">table 4A-D</a>).</p><p>The clinical features, diagnosis, and management of EB are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa"</a> and  <a class="medical medical_review" href="/z/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">PIGMENTATION DISORDERS</span><span class="headingEndMark"> — </span>Melanin, a black or brown pigment formed from tyrosine, is responsible for the color of skin and hair [<a href="#rid27">27</a>]. Melanin is synthesized in melanocytes, which are specialized, dendritic secretory cells derived from the neural crest. These cells migrate to the basal layer of the epidermis during embryogenesis. The presence of melanin in the epidermis helps provide protection from ultraviolet radiation. </p><p>Disorders include decreased and excessive pigmentation. Diagnosis is based on the clinical features in most cases, although some may be clarified with molecular testing. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Oculocutaneous albinism</span><span class="headingEndMark"> — </span>Oculocutaneous albinism (OCA) is a group of rare genetic disorders of melanin biosynthesis inherited in an autosomal recessive pattern [<a href="#rid28">28,29</a>]. There are seven types of OCA caused by mutations in different genes  (<a class="graphic graphic_table graphicRef115427" href="/z/d/graphic/115427.html" rel="external">table 5</a>). Although all types share absent or reduced pigmentation of the hair, skin, and eyes, the clinical phenotypes vary along a broad spectrum of disease severity.</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of OCA are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">"Oculocutaneous albinism"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Ocular albinism</span><span class="headingEndMark"> — </span>Ocular albinism is albinism in which the hypopigmentation is primarily limited to the eyes [<a href="#rid30">30,31</a>]. It is less common than oculocutaneous albinism.</p><p>Ocular albinism type 1 (OA1, MIM #300500), also known as Nettleship-Falls ocular albinism, is the most common form of ocular albinism and has X-linked recessive inheritance. It has an estimated prevalence of 1 in 50,000 to 150,000 live births [<a href="#rid32">32,33</a>].</p><p>The clinical manifestations of OA1 are variable. In affected males, clinical features may include mild cutaneous hypopigmentation, hypopigmentation of the iris and retina, foveal hypoplasia, prominent choroidal vessels, nystagmus, strabismus, head nodding, photophobia, impaired vision, and abnormal crossing of the optic fibers resulting in deficient stereoscopic vision [<a href="#rid31">31,34,35</a>]. Female carriers may have a patchy distribution of retinal pigmentation resulting from X-inactivation [<a href="#rid31">31,36</a>].</p><p>OA1 is diagnosed by careful analysis of the family pedigree for X-linked inheritance and/or molecular analysis of the OA1 gene [<a href="#rid36">36</a>]. The severity of OA1 appears to be related to ethnic background, with individuals from lightly pigmented racial groups more severely affected than those from darkly pigmented groups [<a href="#rid37">37-39</a>]. Life expectancy is normal [<a href="#rid30">30</a>].</p><p>OA1 has been associated with late-onset sensorineural deafness. This form (OASD; MIM 300650) is probably a contiguous gene defect that includes the OA1 gene [<a href="#rid40">40,41</a>]. Another form of ocular albinism with sensorineural deafness has been linked to chromosome 11 and has autosomal recessive inheritance; this form is also known as Waardenburg syndrome type 2 (MIM 103470) [<a href="#rid42">42</a>]. (See <a class="local">'Waardenburg syndrome'</a> below.)</p><p>Ocular albinism type 2 (OA2, MIM #300600), also known as Forsius-Eriksson type ocular albinism and Aland Island eye disease, is a rare, X-linked disorder with clinical manifestations that include nystagmus, myopia, astigmatism, foveal hypoplasia, reduced visual acuity, pigmentary changes in the retina, and changes in color vision; the optic nerves are normal [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Piebaldism</span><span class="headingEndMark"> — </span>Piebaldism (piebald trait) is a rare, autosomal dominant disorder in which cell proliferation and migration of neural crest-derived melanoblasts are defective. This leads to an abnormal distribution of melanocytes during embryogenesis and results in patchy areas of depigmentation [<a href="#rid43">43</a>]. The disorder is caused by mutations in the cell-surface receptor tyrosine kinase gene (<em>KIT</em>) [<a href="#rid44">44</a>].</p><p>Affected patients have patches of depigmented skin, with hyperpigmented borders occurring principally on the midforehead, neck, anterior trunk, and midextremities  (<a class="graphic graphic_picture graphicRef58857 graphicRef52591 graphicRef71514" href="/z/d/graphic/58857.html" rel="external">picture 7A-C</a>). Normal pigmentation occurs on the hands, feet, back, shoulders, and hips. A white forelock is a common finding. The depigmentation is stable and permanent. Patients with piebaldism are generally otherwise healthy and have normal life spans.</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of piebaldism are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15508.html" rel="external">"Piebaldism"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Waardenburg syndrome</span><span class="headingEndMark"> — </span>Waardenburg syndrome is an autosomal dominant inherited pigmentary disorder in which abnormal distribution of melanocytes during embryogenesis results in patchy areas of depigmentation [<a href="#rid43">43,45,46</a>]. Several forms of Waardenburg syndrome are described. All have the clinical features of type 1, which is characterized by a piebald-like distribution of patchy depigmentation of the hair and skin. Other distinctive noncutaneous features include pigmentary abnormalities of the iris (heterochromia irides) and a broad nasal root, secondary to lateral displacement of the inner canthi of the eyes  (<a class="graphic graphic_picture graphicRef56776" href="/z/d/graphic/56776.html" rel="external">picture 8</a>). Congenital deafness occurs in one in five patients with Waardenburg syndrome, and, conversely, an estimated 2 to 7 percent of cases of congenital deafness result from the disorder [<a href="#rid47">47,48</a>]. Occasional findings in Waardenburg syndrome type 1 include cleft lip and palate and neural tube defects (eg, spina bifida, myelomeningocele) [<a href="#rid49">49</a>].</p><p>Waardenburg syndrome type 1 (MIM #193500) and type 3 (MIM #148820) are caused by mutations in the gene for one of three transcription factors (<em>PAX3</em>), whereas type 2 (MIM #193510) is caused by mutations in the transcription factor <em>MITF</em> [<a href="#rid50">50,51</a>]. Waardenburg syndrome type 4 (MIM #277580) also has features of Hirschsprung disease. This type is a result of biallelic mutation in the genes for the endothelin-B receptor (<em>EDNRB</em>) or its ligand endothelin-B (<em>EDN3</em>) [<a href="#rid52">52,53</a>] or heterozygous mutation in the <em>SOX10</em> gene [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)"</a>.)</p><p class="headingAnchor" id="H29839266"><span class="h1">NEUROCUTANEOUS SYNDROMES</span><span class="headingEndMark"> — </span>Neurocutaneous genetic disorders, also called phacomatoses, may present with a variety of neurologic and cutaneous findings. Examples include neurofibromatosis type 1 (NF1), <em>NF2</em>-related schwannomatosis<strong> </strong>(NF2), and tuberous sclerosis complex. The phacomatoses may be associated with increased risk of childhood cancer [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Neurofibromatosis type 1</span><span class="headingEndMark"> — </span>Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is an autosomal dominant neurocutaneous disorder with nervous system, skeletal, and dermatologic manifestations [<a href="#rid56">56</a>]. It is caused by mutations in the <em>NF1</em> gene, encoding the protein neurofibromin. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>The characteristic skin findings that contribute to establishing the diagnosis are:</p><p class="bulletIndent1"><span class="glyph">●</span>Six or more café-au-lait macules of greatest diameter &gt;5 mm in prepubertal and &gt;15 mm in postpubertal individuals  (<a class="graphic graphic_picture graphicRef69606" href="/z/d/graphic/69606.html" rel="external">picture 9A</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two or more neurofibromas of any type or one plexiform neurofibroma  (<a class="graphic graphic_picture graphicRef82613" href="/z/d/graphic/82613.html" rel="external">picture 9B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Freckling in the axillary or inguinal regions (Crowe sign)  (<a class="graphic graphic_picture graphicRef67532" href="/z/d/graphic/67532.html" rel="external">picture 9C</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h2"><i>NF2</i>-related schwannomatosis</span><span class="headingEndMark"> — </span><em>NF2</em>-related schwannomatosis<strong> </strong>(NF2) is characterized by bilateral vestibular schwannomas (acoustic neuromas), meningiomas of the brain, and schwannomas/neurilemmomas of the dorsal roots of the spinal cord. The disorder typically presents in the teens or soon after puberty with unilateral hearing loss. In contrast to NF1, café-au-lait spots in NF2 are typically few, large, and relatively light in color [<a href="#rid57">57</a>]. NF2 is caused by mutations in the gene encoding the intracellular membrane-associated protein neurofibromin-2 (NF-2), a tumor suppressor, which is also known as merlin [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)"</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Tuberous sclerosis complex</span><span class="headingEndMark"> — </span>Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder that's skin findings are often the first clues to its diagnosis [<a href="#rid59">59,60</a>]. TSC is caused by mutations in one of two genes: <em>TSC1</em>, which encodes hamartin, and <em>TSC2</em>, which encodes tuberin. (See  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p>It is estimated that more than 95 percent of patients with TSC have one of the characteristic skin lesions [<a href="#rid60">60</a>]. The most common lesions are:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypopigmented macules, also known as ash-leaf spots, which are usually elliptical in shape  (<a class="graphic graphic_picture graphicRef61601" href="/z/d/graphic/61601.html" rel="external">picture 10A</a>). These are often present at birth, although a Wood's lamp examination may be required to visualize them.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiofibromas, previously called adenoma sebaceum, which typically involve the malar regions of the face  (<a class="graphic graphic_picture graphicRef54868" href="/z/d/graphic/54868.html" rel="external">picture 10B</a>) and usually become apparent by late childhood or early adolescence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shagreen patches (connective tissue nevi), seen most commonly over the lower trunk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A distinctive brown, fibrous plaque on the forehead, which may be the first and most readily recognized feature of TSC to appear on physical examination of affected neonates and infants  (<a class="graphic graphic_picture graphicRef78688" href="/z/d/graphic/78688.html" rel="external">picture 11</a>) [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H30"><span class="h2">Ataxia-telangiectasia</span><span class="headingEndMark"> — </span>Ataxia-telangiectasia (AT, also known as Louis-Bar syndrome) is an autosomal recessive disorder caused by mutations in the gene designated <em>ATM</em> (<strong>AT</strong> <strong>m</strong>utated). The <em>ATM</em> gene, which is expressed in all tissues in the body, is involved in the detection of DNA damage and plays an important role in cell cycle progression. The pathogenesis of AT is thought to be a defect in DNA repair resulting in increased sensitivity to ionizing radiation, immunodeficiency, and progressive cerebellar Purkinje cell death. </p><p>Patients with AT suffer from progressive cerebellar ataxia and other neurologic abnormalities, oculocutaneous telangiectasias, and immune deficiency. Associated features are an increased incidence of malignancy, radiation sensitivity, and diabetes mellitus caused by insulin resistance. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>.)</p><p class="headingAnchor" id="H29839329"><span class="h1">VASCULAR DISORDERS</span><span class="headingEndMark"> — </span>Inherited syndromes associated with cutaneous vascular abnormalities include ataxia-telangiectasia (AT) and hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome. These disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a> and  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">DISORDERS OF CONNECTIVE TISSUE</span><span class="headingEndMark"> — </span>Abnormalities of connective tissue are frequently expressed in the skin. Thus, multisystem inherited connective tissue disorders, such as Ehlers-Danlos syndrome, Marfan syndrome, and osteogenesis imperfecta, can be classified as genodermatoses. Pseudoxanthoma elasticum and focal dermal hypoplasia are less common connective tissue disorders with prominent skin abnormalities. These disorders are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2943.html" rel="external">"Osteogenesis imperfecta: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15468.html" rel="external">"Pseudoxanthoma elasticum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p></p><p class="headingAnchor" id="H29839606"><span class="h1">X-LINKED DOMINANT DISORDERS</span><span class="headingEndMark"> — </span>Incontinentia pigmenti (IP), focal dermal hypoplasia, CHILD (<strong>c</strong>ongenital <strong>h</strong>emidysplasia with <strong>i</strong>chthyosiform erythroderma and <strong>l</strong>imb <strong>d</strong>efects) syndrome (MIM #308050), and chondrodysplasia punctata (Conradi-Hünermann-Happle syndrome, MIM #302960) are examples of X-linked dominant disorders with cutaneous manifestations [<a href="#rid61">61,62</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'X-linked dominant disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">"Incontinentia pigmenti"</a>.)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">ECTODERMAL DYSPLASIAS</span><span class="headingEndMark"> — </span>The ectodermal dysplasias are a large group of inherited disorders that manifest as developmental anomalies in at least two of the structures derived from the embryonic ectoderm, with at least one involving the skin appendages (hair, nails, sweat glands) or teeth  (<a class="graphic graphic_table graphicRef117077" href="/z/d/graphic/117077.html" rel="external">table 6</a>) [<a href="#rid63">63</a>]. The classic ectodermal dysplasias, including hypohidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia with immune deficiency, and hidrotic ectodermal dysplasia; tumor protein p63-related disorders; and focal dermal hypoplasias are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">"Ectodermal dysplasias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117131.html" rel="external">"Tumor protein p63 (TP63)-related ectodermal dysplasias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p></p><p class="headingAnchor" id="H5358994"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The genodermatoses are a heterogeneous group of rare inherited single-gene disorders with skin manifestations. Recognition is important for the initiation of appropriate dermatologic therapy and detection of other associated abnormalities, including malignancy. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genodermatoses associated with cutaneous neoplasias</strong> – Genodermatoses associated with the development of cutaneous and noncutaneous malignancies include basal cell nevus syndrome  (<a class="graphic graphic_picture graphicRef72687" href="/z/d/graphic/72687.html" rel="external">picture 1</a>), Gardner syndrome, Peutz-Jeghers syndrome (PJS)  (<a class="graphic graphic_picture graphicRef80815" href="/z/d/graphic/80815.html" rel="external">picture 2</a>), and xeroderma pigmentosum (XP)  (<a class="graphic graphic_table graphicRef72060" href="/z/d/graphic/72060.html" rel="external">table 1</a>). (See <a class="local">'Disorders with malignant potential'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of keratinization</strong> – Disorders of keratinization include the ichthyosiform dermatoses  (<a class="graphic graphic_table graphicRef71157" href="/z/d/graphic/71157.html" rel="external">table 2</a> and <a class="graphic graphic_picture graphicRef61258 graphicRef66723 graphicRef128200" href="/z/d/graphic/61258.html" rel="external">picture 12A-C</a>), palmoplantar keratodermas, pachyonychia congenita  (<a class="graphic graphic_picture graphicRef52261" href="/z/d/graphic/52261.html" rel="external">picture 4</a>), and Darier disease  (<a class="graphic graphic_picture graphicRef56168 graphicRef70000" href="/z/d/graphic/56168.html" rel="external">picture 5A-B</a>). (See <a class="local">'Disorders of keratinization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blistering disorders</strong> – Abnormalities in the cohesion of the layers of the epidermis underlie the congenital blistering disorders (ie, the epidermolysis bullosa syndromes), in which blister formation occurs with little or no trauma  (<a class="graphic graphic_picture graphicRef59364 graphicRef73201" href="/z/d/graphic/59364.html" rel="external">picture 13A-B</a>). (See <a class="local">'Epidermolysis bullosa'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital defects of melanin synthesis</strong> – These include oculocutaneous albinism, a group of autosomal recessive disorders resulting in hypopigmentation of the hair, skin, and eyes  (<a class="graphic graphic_table graphicRef115427" href="/z/d/graphic/115427.html" rel="external">table 5</a>); piebaldism; and Waardenburg syndrome  (<a class="graphic graphic_picture graphicRef56776" href="/z/d/graphic/56776.html" rel="external">picture 8</a>). (See <a class="local">'Pigmentation disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurocutaneous syndromes</strong> – Cutaneous findings are often a key to the diagnosis of the most common neurocutaneous syndromes: neurofibromatosis  (<a class="graphic graphic_picture graphicRef69606 graphicRef82613 graphicRef67532" href="/z/d/graphic/69606.html" rel="external">picture 9A-C</a>), tuberous sclerosis complex (TSC)  (<a class="graphic graphic_picture graphicRef61601 graphicRef54868" href="/z/d/graphic/61601.html" rel="external">picture 10A-B</a>), and ataxia-telangiectasia (AT). (See <a class="local">'Neurocutaneous syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Connective tissue disorders</strong> – Multisystem inherited connective tissue disorders include Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum  (<a class="graphic graphic_picture graphicRef80952 graphicRef59135 graphicRef77863" href="/z/d/graphic/80952.html" rel="external">picture 14A-C</a>). (See <a class="local">'Disorders of connective tissue'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked dominant disorders</strong> – X-linked disorders with cutaneous manifestations include incontinentia pigmenti  (<a class="graphic graphic_picture graphicRef58769" href="/z/d/graphic/58769.html" rel="external">picture 15</a>) and focal dermal hypoplasia  (<a class="graphic graphic_picture graphicRef55714" href="/z/d/graphic/55714.html" rel="external">picture 16</a>). (See <a class="local">'X-linked dominant disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectodermal dysplasias</strong> – The ectodermal dysplasias are a large group of inherited disorders that manifest as developmental anomalies in at least two of the structures derived from the embryonic ectoderm, with at least one involving the skin appendages (hair, nails, sweat glands) or teeth  (<a class="graphic graphic_table graphicRef117077" href="/z/d/graphic/117077.html" rel="external">table 6</a>). (See <a class="local">'Ectodermal dysplasias'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Spitz JL. Genodermatoses: A Full-Color Clinical Guide to Genetic Skin Disorders, Williams &amp; Wilkins, 1996.</li><li class="breakAll">Sybert VP. Genetic Skin Disorders, Oxford University Press, 1997.</li><li><a class="nounderline abstract_t">Reyes MA, Eisen DB. Inherited syndromes. Dermatol Ther 2010; 23:606.</a></li><li><a class="nounderline abstract_t">Perniciaro C. Gardner's syndrome. Dermatol Clin 1995; 13:51.</a></li><li><a class="nounderline abstract_t">Griffith CD, Bisset WH. Peutz-Jeghers syndrome. Arch Dis Child 1980; 55:866.</a></li><li><a class="nounderline abstract_t">Scott RJ, Crooks R, Meldrum CJ, et al. Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Clin Genet 2002; 62:282.</a></li><li><a class="nounderline abstract_t">Utsunomiya J, Gocho H, Miyanaga T, et al. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975; 136:71.</a></li><li><a class="nounderline abstract_t">Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.</a></li><li><a class="nounderline abstract_t">Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014; 13:637.</a></li><li><a class="nounderline abstract_t">DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785.</a></li><li><a class="nounderline abstract_t">Porter RM, Lane EB. Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 2003; 19:278.</a></li><li><a class="nounderline abstract_t">Roop D. Defects in the barrier. Science 1995; 267:474.</a></li><li><a class="nounderline abstract_t">McLean WH, Moore CB. Keratin disorders: from gene to therapy. Hum Mol Genet 2011; 20:R189.</a></li><li><a class="nounderline abstract_t">Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol 2010; 63:607.</a></li><li><a class="nounderline abstract_t">Itin PH, Lautenschlager S. Palmoplantar keratoderma and associated syndromes. Semin Dermatol 1995; 14:152.</a></li><li><a class="nounderline abstract_t">Lucker GP, Van de Kerkhof PC, Steijlen PM. The hereditary palmoplantar keratoses: an updated review and classification. Br J Dermatol 1994; 131:1.</a></li><li class="breakAll">Hereditary disorders of cornification. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), W.B. Elsevier Saunders, 2006. p.107.</li><li><a class="nounderline abstract_t">Wilson NJ, O'Toole EA, Milstone LM, et al. The molecular genetic analysis of the expanding pachyonychia congenita case collection. Br J Dermatol 2014; 171:343.</a></li><li><a class="nounderline abstract_t">Shah S, Boen M, Kenner-Bell B, et al. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol 2014; 150:146.</a></li><li><a class="nounderline abstract_t">Eliason MJ, Leachman SA, Feng BJ, et al. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67:680.</a></li><li><a class="nounderline abstract_t">Sakuntabhai A, Ruiz-Perez V, Carter S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21:271.</a></li><li><a class="nounderline abstract_t">Ringpfeil F, Raus A, DiGiovanna JJ, et al. Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation. Exp Dermatol 2001; 10:19.</a></li><li><a class="nounderline abstract_t">Burge S. Darier's disease--the clinical features and pathogenesis. Clin Exp Dermatol 1994; 19:193.</a></li><li><a class="nounderline abstract_t">Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27:40.</a></li><li><a class="nounderline abstract_t">Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.</a></li><li><a class="nounderline abstract_t">Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol 2012; 30:70.</a></li><li class="breakAll">Disorders of pigmentation. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), W.B. Elsevier Saunders, 2006. p.265.</li><li><a class="nounderline abstract_t">Summers CG. Albinism: classification, clinical characteristics, and recent findings. Optom Vis Sci 2009; 86:659.</a></li><li><a class="nounderline abstract_t">Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis 2007; 2:43.</a></li><li class="breakAll">King RA, Hearing VJ, Dreel DJ, Oetting WS. Albinism. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, 2001. p.5587.</li><li><a class="nounderline abstract_t">Spritz RA. Molecular genetics of oculocutaneous albinism. Hum Mol Genet 1994; 3 Spec No:1469.</a></li><li><a class="nounderline abstract_t">Rosenberg T, Schwartz M. X-linked ocular albinism: prevalence and mutations--a national study. Eur J Hum Genet 1998; 6:570.</a></li><li><a class="nounderline abstract_t">van Dorp DB. Albinism, or the NOACH syndrome (the book of Enoch c.v. 1-20). Clin Genet 1987; 31:228.</a></li><li class="breakAll">Albinism, ocular, type I;OA1. In: Online Mendelian Inheritance in Man. Johns Hopkins University. www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300500 (Accessed on November 02, 2006).</li><li><a class="nounderline abstract_t">Shen B, Samaraweera P, Rosenberg B, Orlow SJ. Ocular albinism type 1: more than meets the eye. Pigment Cell Res 2001; 14:243.</a></li><li><a class="nounderline abstract_t">Oetting WS. New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene. Hum Mutat 2002; 19:85.</a></li><li><a class="nounderline abstract_t">O'Donnell FE Jr, Green WR, Fleischman JA, Hambrick GW. X-linked ocular albinism in Blacks. Ocular albinism cum pigmento. Arch Ophthalmol 1978; 96:1189.</a></li><li><a class="nounderline abstract_t">Shiono T, Tsunoda M, Chida Y, et al. X linked ocular albinism in Japanese patients. Br J Ophthalmol 1995; 79:139.</a></li><li><a class="nounderline abstract_t">Lyle WM, Sangster JO, Williams TD. Albinism: an update and review of the literature. J Am Optom Assoc 1997; 68:623.</a></li><li><a class="nounderline abstract_t">Winship I, Gericke G, Beighton P. X-linked inheritance of ocular albinism with late-onset sensorineural deafness. Am J Med Genet 1984; 19:797.</a></li><li><a class="nounderline abstract_t">Winship IM, Babaya M, Ramesar RS. X-linked ocular albinism and sensorineural deafness: linkage to Xp22.3. Genomics 1993; 18:444.</a></li><li class="breakAll">Albinism, ocular, with sensorineural deafness. In: Online Mendelian Inheritance in Man. Johns Hopkins University www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=103470 (Accessed on November 02, 2006).</li><li><a class="nounderline abstract_t">Spritz RA. Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Semin Cutan Med Surg 1997; 16:15.</a></li><li><a class="nounderline abstract_t">Syrris P, Heathcote K, Carrozzo R, et al. Human piebaldism: six novel mutations of the proto-oncogene KIT. Hum Mutat 2002; 20:234.</a></li><li><a class="nounderline abstract_t">Dourmishev AL, Dourmishev LA, Schwartz RA, Janniger CK. Waardenburg syndrome. Int J Dermatol 1999; 38:656.</a></li><li><a class="nounderline abstract_t">Read AP, Newton VE. Waardenburg syndrome. J Med Genet 1997; 34:656.</a></li><li><a class="nounderline abstract_t">Nayak CS, Isaacson G. Worldwide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 2003; 112:817.</a></li><li><a class="nounderline abstract_t">Silan F, Zafer C, Onder I. Waardenburg syndrome in the Turkish deaf population. Genet Couns 2006; 17:41.</a></li><li><a class="nounderline abstract_t">Hart J, Miriyala K. Neural tube defects in Waardenburg syndrome: A case report and review of the literature. Am J Med Genet A 2017; 173:2472.</a></li><li><a class="nounderline abstract_t">Potterf SB, Furumura M, Dunn KJ, et al. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet 2000; 107:1.</a></li><li><a class="nounderline abstract_t">Pingault V, Ente D, Dastot-Le Moal F, et al. Review and update of mutations causing Waardenburg syndrome. Hum Mutat 2010; 31:391.</a></li><li><a class="nounderline abstract_t">Edery P, Attié T, Amiel J, et al. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 1996; 12:442.</a></li><li><a class="nounderline abstract_t">McCallion AS, Chakravarti A. EDNRB/EDN3 and Hirschsprung disease type II. Pigment Cell Res 2001; 14:161.</a></li><li><a class="nounderline abstract_t">Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 1998; 18:171.</a></li><li><a class="nounderline abstract_t">Kampitsi CE, Nordgren A, Mogensen H, et al. Neurocutaneous Syndromes, Perinatal Factors, and the Risk of Childhood Cancer in Sweden. JAMA Netw Open 2023; 6:e2325482.</a></li><li><a class="nounderline abstract_t">Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.</a></li><li class="breakAll">Hurwitz S. Clinical Pediatric Dermatology, 2nd ed, WB Saunders, 1993.</li><li><a class="nounderline abstract_t">Lim JY, Kim H, Kim YH, et al. Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 2003; 302:238.</a></li><li><a class="nounderline abstract_t">Kwiatkowski DJ, Short MP. Tuberous sclerosis. Arch Dermatol 1994; 130:348.</a></li><li><a class="nounderline abstract_t">Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996; 135:1.</a></li><li><a class="nounderline abstract_t">Hardelin JP, Levilliers J, del Castillo I, et al. X chromosome-linked Kallmann syndrome: stop mutations validate the candidate gene. Proc Natl Acad Sci U S A 1992; 89:8190.</a></li><li><a class="nounderline abstract_t">Happle R. X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet 1979; 53:65.</a></li><li class="breakAll">Wright JT, Grange DK, Fete M. Hypohidrotic ectodermal dysplasia. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li></ol></div><div id="topicVersionRevision">Topic 3004 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spitz JL. Genodermatoses: A Full-Color Clinical Guide to Genetic Skin Disorders, Williams &amp; Wilkins, 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sybert VP. Genetic Skin Disorders, Oxford University Press, 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054707" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inherited syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7712650" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gardner's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436458" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12372054" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1117595" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Peutz-Jeghers syndrome: its natural course and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12772087" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25012257" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217736" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Shining a light on xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711220" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phenotypes, genotypes and their contribution to understanding keratin function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7529942" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Defects in the barrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890491" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Keratin disorders: from gene to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643494" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640196" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Palmoplantar keratoderma and associated syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043399" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The hereditary palmoplantar keratoses: an updated review and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043399" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The hereditary palmoplantar keratoses: an updated review and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24611874" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The molecular genetic analysis of the expanding pachyonychia congenita case collection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132595" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pachyonychia congenita in pediatric patients: natural history, features, and impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22264670" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080178" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168576" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8033376" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Darier's disease--the clinical features and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1619075" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Darier-White disease: a review of the clinical features in 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374450" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137229" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inherited epidermolysis bullosa: new diagnostic criteria and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137229" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inherited epidermolysis bullosa: new diagnostic criteria and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390472" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Albinism: classification, clinical characteristics, and recent findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980020" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oculocutaneous albinism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980020" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oculocutaneous albinism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849740" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Molecular genetics of oculocutaneous albinism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9887374" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : X-linked ocular albinism: prevalence and mutations--a national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109790" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Albinism, or the NOACH syndrome (the book of Enoch c.v. 1-20).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109790" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Albinism, or the NOACH syndrome (the book of Enoch c.v. 1-20).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549106" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ocular albinism type 1: more than meets the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11793467" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/666626" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : X-linked ocular albinism in Blacks. Ocular albinism cum pigmento.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7696233" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : X linked ocular albinism in Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354055" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Albinism: an update and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6542750" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : X-linked inheritance of ocular albinism with late-onset sensorineural deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288253" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : X-linked ocular albinism and sensorineural deafness: linkage to Xp22.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288253" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : X-linked ocular albinism and sensorineural deafness: linkage to Xp22.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9125761" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12204004" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Human piebaldism: six novel mutations of the proto-oncogene KIT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517681" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Waardenburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279758" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Waardenburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14535568" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Worldwide distribution of Waardenburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16719276" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Waardenburg syndrome in the Turkish deaf population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686331" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neural tube defects in Waardenburg syndrome: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10982026" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20127975" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Review and update of mutations causing Waardenburg syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630502" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434563" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : EDNRB/EDN3 and Hirschsprung disease type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462749" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : SOX10 mutations in patients with Waardenburg-Hirschsprung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37490289" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurocutaneous Syndromes, Perinatal Factors, and the Risk of Childhood Cancer in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207339" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207339" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604337" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129414" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8776349" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The cutaneous features of tuberous sclerosis: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1518845" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : X chromosome-linked Kallmann syndrome: stop mutations validate the candidate gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/535904" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : X-linked dominant chondrodysplasia punctata. Review of literature and report of a case.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
